Core Viewpoint - The animal vaccine sector has shown a significant increase, with a 4.00% rise, ranking third among concept sectors, driven by notable gains in several stocks [1][2]. Group 1: Sector Performance - As of May 20, the animal vaccine concept increased by 4.00%, with 19 stocks rising, including *ST Xianfeng, which hit the daily limit, and others like Kexing Pharmaceutical, Ruipu Biological, and Kanghua Biological, which rose by 15.56%, 8.41%, and 6.70% respectively [1][2]. - The animal vaccine sector was among the top-performing sectors, alongside cultivated diamonds and pet economy, which rose by 4.10% and 4.08% respectively [2]. Group 2: Capital Inflow - The animal vaccine sector saw a net inflow of 67 million yuan, with 13 stocks receiving net inflows, and 6 stocks attracting over 10 million yuan in net inflows [2]. - Jinhe Biological led the net inflow with 36.88 million yuan, followed by Kexing Pharmaceutical, Dabeinong, and Plk, which received net inflows of 15.38 million yuan, 13.79 million yuan, and 13.60 million yuan respectively [2][3]. Group 3: Capital Flow Ratios - Stocks such as *ST Xianfeng, Kexing Pharmaceutical, and KQ Biotech had the highest net inflow ratios, at 14.17%, 6.56%, and 5.52% respectively [3]. - The top stocks in terms of capital inflow included Jinhe Biological with a turnover rate of 18.22% and a daily increase of 4.40%, and Kexing Pharmaceutical with a turnover rate of 3.46% and a daily increase of 15.56% [3][4].

5月20日，宠物经济板块迎来进一步走强。源飞宠物、天元宠物（20CM）双双2连板，依依股份涨停，路斯股份、创源股份、瑞普生物、佩蒂股份等集体大 涨。 一、行情 二、事件：行业持续升温+产业规模冲刺万亿 1）2025年第五届上海它博会TOPS于5月8-11日在上海世博展览馆举办。数据显示，本次它博会参展人数、成交金额均突破历史。 宠物板块上市公司陆续发出24年报及25年一季报，整体业绩实现了超预期增长，宠物经济仍在高速发展。中美关税战影响较为有限，且长期来看利好高端国 产品牌发展。在行业扩容与国产替代双轮驱动下，国内具备研发及生产能力的大型优质宠食企业市占率有望持续提升。（方正证券） *免责声明：文章内容仅供参考，不构成投资建议 *风险提示：股市有风险，入市需谨慎 2）2025年第27届上海亚洲宠物展览会将于8月20-24日在上海新国际博览中心隆重举行。 3）艾媒咨询《2024-2025年中国宠物行业运行状况及消费市场监测报告》中预测，今年国内宠物产业规模将达到8114亿元，两年后这一数字有望突破1万亿 元。 三、机构解读 目前线上平台纷纷加码宠物板块，淘天宠物超5亿高投入，包含商家激励、新品&内容&品牌激励以 ...

Summary of Key Points from Conference Call Records Industry Overview - The pet industry is experiencing significant growth, driven by domestic brands innovating and moving from low-end to high-end products, particularly in emerging categories like baked pet food. This shift has been aided by rising prices of foreign brands due to import tariffs, leading to increased market share for domestic brands [1][4]. Company Performance Highlights Guai Bao Pet - Guai Bao Pet reported a Q1 revenue of 1.48 billion, a year-on-year increase of 34.8%, with net profit rising 38% to 200 million. The revenue from its own brand grew over 40%, achieving an operating profit margin of 13.8%. Both domestic and international sales increased, with domestic sales up 45% and international sales up 18%. The gross margin was 41.6%, slightly down by 0.5 percentage points, but profitability of the own brand improved significantly. The company expects a growth rate of 30%-40% for its own brand throughout the year [5]. Zhongchong Co. - Zhongchong Co. saw a domestic revenue growth of over 40% for its own brand in Q1, with overseas business growing approximately 20%. The second factory in the U.S. will increase North American capacity to 3 billion, effectively mitigating geopolitical risks. The "Wang Pi" brand has shown a growth rate of over 40% for two consecutive quarters, marking the best development phase since its listing [6]. Repu Bio - Repu Bio's Q1 revenue grew by 54%, with profits increasing by 33%. The livestock vaccine segment maintained steady growth, with a 21% increase in revenue from the livestock sector. The company plans to increase the share of its Chinese supply chain from 24% to 70%-80% over the next two years [7]. Natural Pet Food Company - The Natural Pet Food Company announced the acquisition of East China Technology, aiming to establish a comprehensive online and offline channel. The company anticipates achieving total revenue of 500-1,000 million, corresponding to a market value increase of 3-4 billion. The main segment is expected to generate around 100 million in profit, with a valuation of about 20 times, indicating it is at a relatively low point in its growth phase [8]. Investment Recommendations - The pet industry is characterized by high demand and scarcity, suggesting a sector-wide allocation is advisable. Key recommendations include Guai Bao Pet, Zhongchong Co., and Repu Bio, with projected profits for Guai Bao Pet at 840 million in 2025 and 1.12 billion in 2026, and similar growth expectations for the other two companies [2]. Market Trends and Future Outlook - The pet health product sector is identified as a new blue ocean market, transitioning from initial stages to a long-term high-growth window. The consumption of pet health products in China is significantly lower than in the U.S. and Japan, indicating substantial growth potential [3][9]. - The long-term development logic of the pet industry is based on the increasing perception of pets as family members, particularly in urban areas. This trend is expected to drive the premium pet market, with the European pet premium market projected to reach 1.7 billion euros by 2024, growing at an annual rate of about 14% [10]. Challenges and Opportunities - The pet food industry faces opportunities from the growing trend of pet health product consumption. However, challenges include the relatively small domestic market and the need for companies to adapt to changing consumer preferences and behaviors [14][18]. - The entry of human health product companies into the pet health product sector is seen as advantageous due to their established production techniques and supply chain management capabilities, which can enhance the overall industry landscape [15][16][17]. Conclusion - The pet industry in China is poised for significant growth, driven by innovation, changing consumer behaviors, and the increasing humanization of pets. Companies that adapt to these trends and leverage their strengths in supply chain and product development are likely to succeed in this evolving market [12][13].

作者 | 守望者 来源 | 守望核心 导语： 拆解宠物板块持续新高背后的三大预期与核心标的逻辑。 宠物板块持续新高的背后市场在交易什么预期，借助公开资料，理一下宠物板块的β及选股思路， 以及个股的核心看点 。 一、大背景 宠物经济蓬勃发展的内核是宠物的 "人格化、家人化" ， 年轻一代将宠物视为"家人"的情感价值重 构。 1、宠物经济正是基于这一情感纽带蓬勃发展，从提供高品质的宠物食品、个性化的宠物用品，满 足宠物的物质需求； 2、到宠物医疗、保险，为宠物的健康保驾护航； 3、再到宠物美容、摄影、社交活动等，满足主人与宠物之间情感互动的精神需求。 每一个细分领域，让宠物真正融入家庭生活，也让宠物经济的内涵和外延得以不断拓展和深化 。 二、宠物是一个大赛道 1、横向对比化妆品、白酒、食品等来看， 宠物赛道是消费里面少有量价齐升的板块 ，并且随着单 身经济及消费方式的转变， 从实物消费到情绪消费的转变 ，相信大家多少在家里面都多少有一些 宠物（常见的是猫、狗，稀罕的是鸟、仓鼠、乌龟、蛇等），宠物恰逢其时，目前A股从宠物食品 到医疗已经形成一个完整的贝塔。 C、主业稳健，每年贡献净利润大几千万，收购的淘通科技可以贡 ...

Group 1 - The Tianjin Free Trade Zone concept rose by 3.51%, ranking second among concept sectors, with 13 stocks increasing, including Haitai Development which hit the daily limit, and Tianjin Port, Bohai Chemical, and Tianjin Pulin showing significant gains of 6.93%, 5.85%, and 5.55% respectively [1][2] - The main capital inflow into the Tianjin Free Trade Zone concept was 96 million yuan, with 9 stocks receiving net inflows, and 5 stocks seeing inflows exceeding 10 million yuan, led by Bohai Chemical with a net inflow of 32.42 million yuan [2][3] - The net inflow ratios for leading stocks were 21.19% for Haitai Development, 7.42% for Bohai Chemical, and 5.24% for Tianjin Pulin, indicating strong investor interest [3][4] Group 2 - The top-performing concept sectors today included the Armament Reorganization concept at 3.92% and the Tianjin Free Trade Zone at 3.51%, while sectors like Artemisinin and Humanoid Robots experienced declines of -0.82% and -0.80% respectively [2] - The trading volume and turnover rates for key stocks in the Tianjin Free Trade Zone concept were notable, with Bohai Chemical at a turnover rate of 10.64% and Tianjin Port at 3.20% [3][4] - The overall market sentiment reflected a positive trend for the Tianjin Free Trade Zone concept, with significant capital inflows and stock performance indicating potential growth opportunities [1][2]

Group 1 - The animal vaccine sector saw an increase of 1.28%, ranking 8th among concept sectors, with 13 stocks rising, including Reap Bio, Blue Biological, and Yongshun Biological, which rose by 6.01%, 4.42%, and 4.36% respectively [1][2] - The leading stocks in terms of net inflow of main funds were Reap Bio with a net inflow of 9.98 million yuan, followed by Tiankang Biological, Kexing Pharmaceutical, and Biological Shares with net inflows of 9.45 million yuan, 5.12 million yuan, and 1.64 million yuan respectively [2][3] - The main fund inflow ratios were led by Shunlian Biological, Kexing Pharmaceutical, and Tiankang Biological, with net inflow ratios of 7.59%, 5.97%, and 5.13% respectively [3] Group 2 - The stocks with the largest declines included *ST Xianfeng, Haili Biological, and Ronioushan, which fell by 4.97%, 0.72%, and 0.66% respectively [1][4] - The overall trend in the animal vaccine sector indicates a mixed performance, with some stocks experiencing significant gains while others faced declines [1][4] - The trading volume and turnover rates varied significantly among the stocks, with some showing high turnover rates despite negative price movements [4]

公司 2024 年度权益分派方案已经 2025 年 4 月 24 日召开的 2024 年年度股 东大会审议通过，现将权益分派事宜公告如下： 一、股东大会审议通过利润分配及资本公积金转增股本方案等情况 1、公司 2024 年年度权益分派方案已获 2025 年 4 月 24 日召开的 2024 年年 度股东大会审议通过，权益分派方案具体内容如下：以公司现有总股本 465,847,906 股扣减回购专用证券账户 10,093,859 股后的 455,754,047 股为基数， 向全体股东每 10 股派发现金红利 3.00 元（含税），预计派发现金股利 136,726,214.10 元（含税）。本年度不送红股，不以资本公积转增股本。在本次 利润分配预案披露之日起至实施权益分派股权登记日期间，如公司总股本发生变 动，公司将按照"现金分红比例不变"的原则做相应调整。 证券代码：300119 证券简称：瑞普生物 公告编号：2025-043 瑞普生物股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、瑞普生物股份有限公 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-042 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示： 1、本次股东大会无变更、否决议案的情况； 2、本次股东大会以现场投票、网络投票相结合的方式召开。 一、会议召开和出席情况 瑞普生物股份有限公司（以下简称"公司"）2025年4月26日以董事会公告方式 向全体股东发出召开2025年第二次临时股东大会的通知。（公告编号：2025-039）。 本次股东大会采取现场投票、网络投票相结合的方式召开。其中现场会议于2025 年5月12日下午14:30在公司会议室召开，会议由董事长李守军先生主持；通过深圳证 券交易所系统进行网络投票的时间为2025年5月12日09:15-09:25，09:30-11:30，13:00- 15:00；通过深圳证券交易所互联网系统投票的具体时间为2025年5月12日09:15- 15:00期间的任意时间。 公司总股本465,847,906股，扣除公司股份回购专户的股份数后，公司有表决权 股份总数为455,160,547股。出席现场和网络投票的股东171人，代表股份1 ...

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于瑞普生物股份有限公司 2025 年第二次临时股东大会的法律意见书 致：瑞普生物股份有限公司 受瑞普生物股份有限公司(以下简称"公司")聘请，北京市通商律师事务所 指派律师(以下简称"本所律师")出席了公司 2025 年第二次临时股东大会(以下 简称"本次股东大会")，并依据《中华人民共和国公司法》(以下简称"《公司 法》")、《上市公司股东会规则》、《深圳证券交易所上市公司股东会网络投票 实施细则》等法律、法规、规章、规范性文件及《瑞普生物股份有限公司章程》 (以下简称"《公司章程》")的规定，对公司本次股东大会召集及召开程 ...

Investment Rating - Industry Rating: Outperform the market (maintained rating) [12] Core Views - The pet sector continues to show high prosperity, driven by domestic substitution and consumption upgrades, leading to a dual increase in volume and price [1][2] - The industry is transitioning from "scale expansion" to "value creation," with leading companies shifting from "manufacturing" to "intelligent manufacturing" through formula innovation and precise demand capture [2][17] - The domestic pet food market remains strong, with a significant increase in sales and exports, indicating robust growth potential for domestic brands [2][17] Summary by Sections Pet Sector - The fifth TOPS Pet Expo in Shanghai showcased over 1,200 exhibitors and 8,000+ brands, reflecting strong growth momentum in the pet industry, with a 43% year-on-year increase in attendance [1][16] - Trends in pet food are shifting towards precision nutrition, with a focus on age-specific feeding and high-end production techniques [1][16] - Key recommended companies in the pet food sector include Guibao Pet, Zhongchong Co., Petty Co., and Lusi Co., with additional recommendations for pet medical and product companies [2][17] Swine Sector - As of May 10, the average price of live pigs was 14.90 yuan/kg, showing a slight decline, with production capacity continuing to grow [3][18] - The industry is facing a potential downturn in profitability due to weak demand and seasonal price declines [3][19] - Recommended companies include leading players such as Wens Foodstuffs and Muyuan Foods, with a focus on core assets [19] Poultry Sector - The white chicken segment is facing uncertainties in breeding imports, with a significant decline in the number of breeding stock updated [20][21] - The yellow chicken segment is expected to benefit from improved consumer demand, with stable prices observed [23] - Recommended companies include Shengnong Development and Lihua Co. for white chicken, and Wens Foodstuffs for yellow chicken [22][23] Planting Sector - The government emphasizes agricultural technology innovation and self-sufficiency in food security, with a focus on biological breeding [25][26] - Recommended companies in the seed sector include Longping High-Tech and Dabeinong, with additional focus on agricultural water-saving technologies [25][26] Feed and Animal Health Sector - Hai Da Group is highlighted for its market share growth and consistent performance in the feed sector [27] - The animal health sector is seeing new opportunities in pet health products, with recommended companies including KQ Bio and Zhongmu Co. [28]